PMID- 36621291
OWN - NLM
STAT- MEDLINE
DCOM- 20230330
LR  - 20230330
IS  - 1096-3618 (Electronic)
IS  - 1044-5323 (Linking)
VI  - 66
DP  - 2023 Mar
TI  - Natural killer cells and type 1 innate lymphoid cells in cancer.
PG  - 101709
LID - S1044-5323(22)00127-0 [pii]
LID - 10.1016/j.smim.2022.101709 [doi]
AB  - Innate lymphoid cells (ILCs) are a group of innate lymphocytes that do not 
      express RAG-dependent rearranged antigen-specific cell surface receptors. ILCs 
      are classified into five groups according to their developmental trajectory and 
      cytokine production profile. They encompass NK cells, which are cytotoxic, 
      helper-like ILCs 1-3, which functionally mirror CD4(+) T helper (Th) type 1, Th2 
      and Th17 cells respectively, and lymphoid tissue inducer (LTi) cells. NK cell 
      development depends on Eomes (eomesodermin), whereas the ILC1 program is 
      regulated principally by the transcription factor T-bet (T-box transcription 
      factor Tbx21), that of ILC2 is regulated by GATA3 (GATA-binding protein 3) and 
      that of ILC3 is regulated by RORgammat (RAR-related orphan receptor gamma). NK cells were 
      discovered close to fifty years ago, but ILC1s were first described only about 
      fifteen years ago. Within the ILC family, NK and ILC1s share many similarities, 
      as witnessed by their cell surface phenotype which largely overlap. NK cells and 
      ILC1s have been reported to respond to tissue inflammation and intracellular 
      pathogens. Several studies have reported an antitumorigenic role for NK cells in 
      both humans and mice, but data for ILC1s are both scarce and contradictory. In 
      this review, we will first describe the different NK cell and ILC1 subsets, their 
      effector functions and development. We will then discuss their role in cancer and 
      the effects of the tumor microenvironment on their metabolism.
CI  - Copyright (c) 2023 Elsevier Ltd. All rights reserved.
FAU - Lopes, Noella
AU  - Lopes N
AD  - Aix Marseille Universite, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, 
      Marseille, France.
FAU - Vivier, Eric
AU  - Vivier E
AD  - Aix Marseille Universite, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, 
      Marseille, France; Innate Pharma Research Laboratories, Innate Pharma, Marseille, 
      France; APHM, Hopital de la Timone, Marseille-Immunopole, Marseille, France.
FAU - Narni-Mancinelli, Emilie
AU  - Narni-Mancinelli E
AD  - Aix Marseille Universite, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, 
      Marseille, France. Electronic address: narni@ciml.univ-mrs.fr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230106
PL  - England
TA  - Semin Immunol
JT  - Seminars in immunology
JID - 9009458
SB  - IM
MH  - Animals
MH  - Humans
MH  - Mice
MH  - *Immunity, Innate
MH  - *Killer Cells, Natural
MH  - *Lymphocytes
MH  - Lymphoid Tissue/metabolism/pathology
MH  - *Neoplasms/immunology
MH  - T-Lymphocytes, Helper-Inducer
MH  - Tumor Microenvironment
COIS- Declaration of Interests E.V is a cofounder and employee of Innate Pharma. The 
      other authors report no declarations of interest.
EDAT- 2023/01/10 06:00
MHDA- 2023/03/21 06:00
CRDT- 2023/01/09 04:47
PHST- 2022/08/24 00:00 [received]
PHST- 2022/12/17 00:00 [revised]
PHST- 2022/12/23 00:00 [accepted]
PHST- 2023/01/10 06:00 [pubmed]
PHST- 2023/03/21 06:00 [medline]
PHST- 2023/01/09 04:47 [entrez]
AID - S1044-5323(22)00127-0 [pii]
AID - 10.1016/j.smim.2022.101709 [doi]
PST - ppublish
SO  - Semin Immunol. 2023 Mar;66:101709. doi: 10.1016/j.smim.2022.101709. Epub 2023 Jan 
      6.